|Mr. Jack A. Khattar||Founder, Pres, CEO, Sec. & Director||1.42M||N/A||1961|
|Mr. Gregory S. Patrick||Sr. VP & CFO||539.35k||4.37M||1951|
|Dr. Padmanabh P. Bhatt||Chief Scientific Officer & Sr. VP of Intellectual Property||533.53k||5.08M||1957|
|Dr. Stefan K. F. Schwabe||Chief Medical Officer and Exec. VP of R&D||582.88k||2.74M||1952|
|Dr. Todd Horich M.B.A., Ph.D.||VP of Marketing||N/A||N/A||N/A|
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 7; Compensation: 5.